INHIBITION OF TAU POLYMERIZATION WITH A CYANINE DYE IN TWO DISTINCT MODEL SYSTEMS

Erin E. Congdon, Yvette H. Figueroa, Lili Wang, Galina Toneva, Edward Chang, Jeff Kuret, Christopher Conrad, & Karen E. Duff*

1Taub Institute / Department of Pathology, Columbia University and Dept of Integrative Neuroscience, New York State Psychiatric Institute, New York, USA.
2Ohio State University, Ohio, Integrated Biomedical Science program
3Ohio State University, Ohio, Cellular and Molecular Biology

Running Head: Tau Aggregation Inhibitor C11

Address Correspondence to: Karen E. Duff, P&S 12th Flr Rm 12-461, Columbia University Medical Center, New York, NY 10032, Phone: 212-305-8790, Fax: 212-342-0119, Email: ked2115@columbia.edu

In a host of neurodegenerative diseases tau, a microtubule associated protein, aggregates into insoluble lesions within neurons. Previous studies have utilized cyanine dyes as tau aggregation inhibitors in vitro. Herein we utilize cyanine dye 3,3'-Diethyl-9-methyl-thiacarbocyanine iodide (C11) to modulate tau polymerization in two model systems, an organotypic slice culture model derived from tau transgenic mice and a split Green Fluorescent Protein (GFP) complementation assay in tau-expressing cells. In slice cultures, submicromolar concentrations (0.001 µM) of C11 produced a significant reduction of aggregated tau and a corresponding increase in unpolymerized tau. In contrast, treatment with a 1 µM dose promoted aggregation of tau. These results were recapitulated in the complementation assay where administration of 1 µM C11 produced a significant increase in polymerized tau relative to control whereas treatment of cells with 0.01 µM C11 resulted in a marked reduction of aggregated tau. In the organotypic slice cultures, modulation of tau aggregation was independent of changes in phosphorylation at disease and microtubule binding relevant epitopes for both dosing regimes. Further, treatment with 0.001 µM C11 resulted in a decrease in both total filament mass and number. There was no evidence of apoptosis or loss of synaptic integrity at either dose however, while submicromolar concentrations of C11 did not interfere with microtubule binding, higher doses resulted in a decrease in the levels of microtubule-bound tau. Overall, a cyanine dye can dissociate aggregated tau in an ex vivo model of tauopathy with little toxicity and exploration of the use of these type of dyes as therapeutic agents is warranted.

Introduction

Abnormal accumulation of aggregated proteins is a common feature of many neurodegenerative disorders including Parkinson’s, Huntington’s and Alzheimer’s disease (AD). The defining lesions in AD include the extracellular plaques composed of amyloid β and intracellular polymers of the microtubule associated protein tau. Under normal conditions, as much as 90% of the tau expressed in neurons is bound to microtubules providing stability for the cytoskeleton. In addition, tau may also play a role in the microtubule interactions of both Golgi membranes and dynein [1, 2].

Intracellular tau aggregates are a defining feature in a host of neurodegenerative disorders including AD, corticobasal degeneration and frontotemporal dementia. Development of neurofibrillary pathology in AD follows a highly stereotyped pattern [3, 4] and the appearance of tangles correlates with both neuronal loss and severity of cognitive symptoms [5-7]. Evidence suggests that tau polymerization may also be directly linked to degeneration. Mutations in the tau gene are sufficient to cause familial cases of frontotemporal dementia and the disease causing mutations have been shown to alter the propensity
for secondary structure and to promote tau aggregation in vitro [8-10]. Transgenic animals expressing aggregation-prone mutant tau develop synaptic dysfunction [11]. In contrast, animals expressing tau containing an aggregation-inhibiting mutation displayed no changes in synapse number despite similar levels of hyperphosphorylation [11]. Neurons containing tau polymers have also been shown to have both accumulation of pro-apoptotic caspases as well as signaling deficits [12, 13]. Impaired neurotransmission and morphological changes were observed in lesion bearing neurons in a C. elegans model of tauopathy [14]. Additionally, abnormal tau aggregates have also been found to affect both gene transcription and proteasome activity [15, 16]. In cell culture models higher levels of tau polymerization was correlated with increased cell death [17, 18]. Conversely, treatment with tau aggregation inhibitors reduced levels of cell loss [18, 19]. These findings indicate that development of tau aggregation inhibitors is a potential avenue for the creation of disease modifying therapies.

A number of polymerization inhibitors have been studied including Congo red derivatives, anthraquinones (Pickhardt et al. 2005 [20], disputed in Crowe et al. 2007 [21]), 2,3-di(furan-2-yl)-quinoxalines [21], phenylthiazolyl-hydrazide (PTH) [22, 23], polyphenols and porphyrins [24], and cyanine dyes [25-27]. Cyanine dyes were identified in a small molecule screen as tau fibrillization antagonists. Of these, 3-(2-hydroxyethyl)-2-[2-[3-(2-hydroxyethyl)-5-methoxy-2-benzthiazolylidene)methyl]-1-butenyl]-5-methoxybenzothiazolium (N744) has been well characterized utilizing in vitro assays [25-27]. N744 was capable of inhibiting filament formation at substoichiometric concentrations with an IC50 of 294 ± 23 nM [25]. Analysis utilizing electron microscopy revealed that N744 was capable of reducing both total filament mass and filament number. Also, substoichiometric concentrations of N744 were capable of disaggregating mature filaments. Over 19 hours of incubation total filament length was reduced to 13 ± 2% of the control [25]. In contrast to other polymerization inhibitors, length distribution remained unchanged with N744 treatment. This is not inconsequential as these results indicate that disaggregation was endwise rather than the result of random breakage. Interestingly, further study revealed that N744 activity is biphasic with optimal inhibition occurring at ~ 4µM [26]. Above this concentration, inhibition is relieved and polymerization levels greater than control samples are observed at higher drug concentrations. These changes are reflected by changes in the equilibrium constant, or minimal concentration, for tau polymerization. In the inhibitory range, increasing doses of N744 produced corresponding increases in the critical concentration. In contrast, higher concentrations of N744 resulted in a lowering of the equilibrium constant. Though N744 is not capable of directly triggering tau polymerization, it appears capable of increasing the concentration of tau available for incorporation into fibrils by competitively binding to the negatively charged surfaces presented by polymerization inducers [26]. These findings demonstrate the potential usefulness of cyanine dyes as candidates for development as therapeutics and use in hypothesis testing.

Within the cyanine dye family, there are multiplex commercially available molecules which vary with respect to the meso substituent, bridge length, and N substituent. Of these, 3,3'-Diethyl-9-methylthiacarbocyanine iodide (C11) was found to have a similar potency in vitro to N744. [28] In addition, the molecular properties of C11 present distinct advantages compared to N744. Comparisons of topological polar surface area (tPSA), octanol water partition coefficient (miLogP), and molecular weight indicate that C11 have a similar potency to N744 for tau polymerization. In the inhibitory range over a wide concentration range in a transfected cell and an ex vivo culture system making aggregated, tangle-type tau. An inactive cyanine, C2, was used to control for non-specific effects of the cyanine scaffold. Two different culture systems were utilized to assay the effects of cyanine treatment on tau polymerization. In the first, organotypic slices were cultured from the hTau mouse line which expresses all six isoforms of wild type human tau. Slice cultures accumulate a robust level of aggregated tau in a physiologically relevant milieu. In addition, because the hemispheres are plated separately, one hemisphere may be retained to serve as a within-animal control, thus eliminating the problem of...
variable aggregate levels between animals. A second culture system utilized human embryonic kidney (HEK) cells transfected with split GFP labeled tau. In this assay, GFP fluorescence is altered upon tau aggregation with higher degrees of polymerization resulting in reduced GFP signal. [29] This system allows for a high number of replicates as well as fast and quantitative measurements. Results show that C11 is capable of significantly reducing levels of aggregated tau at submicromolar concentrations (0.001 μM) with no effects on polymerization with C2. In addition, these effects were not dependent on changes in phosphorylation state.

**Experimental Procedures**

**Animals**- To generate the hTau line, transgenic mice (line 8c, [30]) were crossed to a targeted line in which the endogenous mouse tau gene was non-functional [31]. Pups at postnatal day 10 from the hTau mouse line [32] of either sex were utilized for organotypic slice cultures. The hTau line expresses all six isoforms of human wild-type tau under the control of the human tau promoter due to integration of a PAC derived human genomic sequence. Animals were used in accordance with National Institute of Health/Institutional Animal Care and Use guidelines.

**Antibodies**- The following monoclonal anti-tau antibodies were used, CP27 (total human tau) and PHF-1 (phosphoSer\(^{396/404}\)) were gifts from Dr. Peter Davies (Albert Einstein, New York, NY). AT8 (phospho-Ser\(^{202/205}\)), phospho-Thr\(^{212}\) monoclonal antibody was purchased from Thermo (Rockford, IL). Phospho-Ser\(^{262}\), and phospho-Ser\(^{396}\) were obtained from Biosource (Camarillo, CA). Monoclonal anti-α-tubulin and synaptophysin antibodies were purchased from Sigma Aldrich. Anti-cleaved PARP antibody was obtained from Cell Signaling (Danvers, MA).

**Preparation of organotypic slices**- Organotypic slice cultures were prepared utilizing protocols modified from Duff et al. [33] (depicted in Figure 1). Brains were removed from hTau pups at postnatal day ten. Hemispheres (cortex and hippocampus) were sectioned into 400 μm thick slices and separated in ice-cold buffer (pH 7.1). Slices (~18 per hemisphere) were transferred to membrane inserts containing 0.4 μm pores (Laboratory Disposable Products; Wayne, NJ). Following sectioning, slices were allowed to incubate in culture for 14 days in media containing 25% serum. Media was exchanged every two days. Following the incubation period slices comprising each hemisphere were treated with either C11 (Sigma Aldrich) or DMSO vehicle (final concentration of DMSO in media 0.008%), thus allowing the DMSO treated slices to serve as a within-animal control. C11 treated slices were dosed at 1.0, 0.1 or 0.001 μM (n=6 mice per group). This compound is structurally similar to a previously identified tau polymerization antagonist N744 and it has a similar dose response curve \textit{in vitro}. Additional slices (n=5 mice) were treated with either 0.001 μM C2 (an inactive cyanine) or DMSO control (final concentration of DMSO in media 0.008%).

**Tissue fractionation**- Tissue fractionation procedures were adapted from Greenberg and Davies (1990) [34]. Control and C11 or C2 treated slices were homogenized in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM Na\(_3\)VO\(_4\), 1μg/ml protease inhibitors, 1μg/ml phosphatase inhibitors) and centrifuged at 20,000 G at 4°C for 20 minutes. The pellet fraction was discarded and the resulting supernatant assayed for total protein concentration. Samples were then diluted as necessary to achieve equivalent total protein levels. In order to generate the heat stable (S) fraction an aliquot of the low speed supernatant was retained and boiled for 10 minutes. After heating, the samples were centrifuged at 20,000 x G for 20 minutes at 4°C and the supernatant was retained and diluted in O+ buffer (62.5 mM Tris-HCl pH 6.8, glycerol 5%, 2-mercaptoethanol, 2.3% SDS, 1mM EGTA, 1mM PMSF, 1mM NaVO\(_4\), 1 μg/ml protease inhibitors, 1 μg/ml phosphatase inhibitors). The S fraction represents soluble tau. In order to isolate tau polymers, an additional fraction of low speed supernatant was incubated in 1% sarkosyl for 30 minutes at room temperature. Samples were then centrifuged for 1 hour at 100,000 x G at 20°C. Supernatant was discarded and the sarkosyl insoluble (SI) pellet was resuspended in 20 μL O+ buffer.
Estimation of C11 concentration - Because the effects of C11 are mediated by dye concentration, determining the level of compound in the target tissue may explain the observed effects on tau polymerization. Slices were washed three times in PBS to remove dye bound to the surface of the tissue. Slices were then collected as described above and centrifuged at 20,000 x G for 20 minutes at 4°C. Supernatant fractions were removed and reserved for determination of C11 concentration. In order to generate a standard curve, varying concentrations of C11 (0.001-10 µM) were incubated in untreated tissue homogenates overnight at 37°C in a 96 well plate. Following incubation, homogenates from control and treated samples were added to the plate in triplicate. Fluorescence data was collected using a TECAN Infinite M200 plate reader, excitation 550 nm, emission 585 nm [35]. Average and standard deviation for each sample and standard was calculated. The average fluorescence of each standard was then plotted against C11 concentration to generate a standard curve. Slope of the resultant line was determined and utilized to estimate dye concentration in the treated samples.

Preparation of samples for electron microscopy - Sarkosyl insoluble fractions from control and treated slices were prepared as described above with the exception that the final pellet was resuspended in 100 µL PBS. Samples were fixed with glutaraldehyde (2% final volume) and adsorbed onto 400 mesh copper electron microscope grids (Electron Microscopy Sciences; Ft. Washington, PA) for 20 minutes. Grids were then washed with double distilled water. Grids were then stained with uranyl acetate (Electron Microscopy Sciences) at 2% final volume for 5 minutes. Following staining, grids were washed a second time.

Microtubule binding assay - Because C11 is capable of binding to the tau protein it is important to ascertain whether the presence of the drug interferes with normal microtubule binding, which is potentially detrimental. Additional slices were prepared and treated as described above with either 1.0 or 0.001 µM C11. Microtubule binding assays were conducted utilizing methods adapted from Volgelsberg-Ragaglia (2000 [36]). Samples were homogenized in warm (37°C) RAB buffer (0.1 M MES pH 6.8, 0.5 mM MgSO4, 1 mM EGTA, 1% Triton X-100, 20 µM Taxol, 2 mM GTP, phosphatase inhibitor cocktail, protein inhibitor cocktail) using a warmed Dounce homogenizer. Samples were centrifuged at 3,000 x G for 4 minutes at 25°C to remove debris. The resulting supernatant was collected and a 50 µL aliquot was diluted in O+ buffer and boiled for 5 minutes. A 100 µL aliquot of the remaining supernatant was centrifuged at 100,000 x G for 20 minutes at 25°C. The supernatant was collected and the pellet was resuspended in 100 µL RAB buffer. Fifty µl fractions of both the supernatant and pellet fractions were diluted in 450 µL O+ buffer and boiled. Immuno blotting was carried out on the total, cytosolic (free), and microtubule bound fractions with CP27 as the primary antibody.

Quantitative immunoblot analysis - Membranes were blocked for 30 minutes in PBS containing 5% milk. Appropriate dilutions of primary and secondary antibodies were applied. Bands were visualized with enhanced chemiluminescence reagent (Immunobilon Western HRP substrate luminol reagent, Millipore) using a Fujifilm LAS3000 imaging system in the linear range. Signal was quantified using Multigauge version 3.0.

Filament quantification - Random images from each grid were obtained using a JEOL 1200 transmission electron microscope operated at 80 kV at 12,000x magnification. Images were imported into Image J and individual filaments were traced manually to obtain length data. These methods have been well established in multiple in vitro studies [37-39]. Total length and filament number were averaged over each condition and standard deviation calculated. For each image the total number of filaments in each 10 nm length range, or bin, was determined and expressed as a percentage of total filament number. The percentage of filaments per bin was then averaged and plotted against length interval midpoint.

Plasmid construction - Plasmids were generated as previously described. [29] Briefly, the small fragment of GFP was amplified by PCR and cloned into XbaI and Apal sites of pcDNA3.1 (+).
pcDNA3.1 (-)-T4 was used to generate human tau isoform 24 (containing exon ten but lacking exons two and three). In order to obtain tau-GFP, tau PCR products were cloned into the Kpn I and Xba I sites of the pcDNA3.1 (+) with the GFP vector. The large GFP fragment was cloned into the Nhe I and Not I sites of pcDNA3.1 (-).

Cell Culture- Human embryonic kidney (HEK) cells were grown in clear bottom 96 well plates in OPTI-MEM (Cellgro, Herndon, VA) with media exchanged every other day. Cells were allowed to incubate in culture for either one or two days post transfection following which they were treated with either C11 or DMSO vehicle (DMSO final concentration in media 0.3%).

Detection of GFP and C11- GFP complementation was measured daily using a TECAN Infinite M200 plate reader with an excitation wavelength of 485 nm and an emission wavelength of 520. C11 fluorescence was measured concurrently. Signal was averaged over wells in each condition (n=8) and plotted as percent of initial value against time.

Analytical Methods- Chemiluminescence signal was determined as described above. For each sample signal relative to control was determined for each treated samples. Average and standard error was determined for each group. Statistical significance was determined utilizing a two tailed Student T’s test.

Results

C11, but not C2 is capable of modulating tau polymerization in organotypic slice cultures. Tissue fractionation was performed as described above for slices (n=6 mice per group) treated with C11, C2 and vehicle control. All fractions were subjected to immunoblotting with CP27, an antibody against human tau (Figure 3). No significant change in total tau levels was observed in any C11 dosing regime (107.6 ± 15.7 for 0.001 µM, 98.03 ± 6.4 for 0.1 µM, and 94.1 ± 6.53 for 1 µM C11) relative to control. In addition, no change was seen in the levels of tau in the soluble fraction relative to control in slices treated with 0.1, or 1 µM C11 (94.1 ± 10.6 and 108.1 ± 22.5). However, treatment with 0.001 µM C11 resulted in a significant increase (p = 0.01) in soluble tau. This increase in unpolymerized tau is mirrored by a reduction in the levels of aggregated protein. Addition of 0.001 µM C11 to culture media produced a significant reduction (p = 0.003) in sarkosyl insoluble tau relative to untreated slices from the same animal (55 ± 27.7). In contrast, incubation with 1 µM C11 resulted in significantly elevated (p = 0.001) levels of polymerized tau (305.43 ± 86.9). No change was observed in slices treated with 0.1 µM (101.3 ± 7.9). These results indicate that the biphasic effects observed with cyanine dyes incubated with recombinant tau in vitro are also present in cultured tissue [26]. However, compared to in vitro studies, much lower doses were required to achieve inhibition. Because 1 µM and 0.001 µM doses produced significant and opposing effects on tau polymerization, they were chosen for further investigation. No change in the concentration of aggregated tau was observed following treatment with compound C2, indicating that the compound is ineffective against tau polymerization in culture as well as in recombinant protein.

C11 is detectable in slice homogenate. Fluorescence measurements were obtained in triplicate for each standard, control, and treated sample. Values recorded from the standard samples were averaged and plotted against C11 concentration to generate the standard curve (Figure 4.A). The equation for the resultant line was calculated as: y = 10442x + 128.17, with an R² value of 0.991. Average fluorescence was then calculated for each of the control and treated samples with values of 32504 ± 8212.9 and 183.2 ± 61.7 for 1 µM (Figure 4.B) and 0.001 µM (Figure 4.C) respectively. Utilizing Equation 1, the concentration of C11 in treated slices was estimated as 0.0053 µM and 3.101 µM for the 0.001 and 1 µM dosing regimes, thereby indicating that the drug is taken up and concentrated by the tissue.

Changes in tau polymerization are not dependent on changes in phosphorylation. Because hyperphosphorylation has been postulated as a polymerization promoter [40-43] and multiple aggregation inhibitors act via effects on protein kinases [44-46], an examination of whether C11
also affects phosphorylation was performed. The heat stable fraction from control, C11, and C2 treated slices were subjected to immunoblotting to assay for changes in phosphorylation state (Figure 5.A). However, no changes in occupancy were seen in either C11 dosing regime or with C2 treatment at Ser\textsuperscript{202/205} (AT8), Thr\textsuperscript{212}, Ser\textsuperscript{262}, Ser\textsuperscript{396}, or Ser\textsuperscript{396/404} (PHF-1) sites (Figure 5.B-F). These sites have been implicated in disease or as modulators of polymerization in vitro. These data demonstrate that tau polymerization can be targeted independently of phosphorylation. As tau kinases have multiple targets within the cell, directly targeting abnormal tau may provide a way to reduce the unwanted side effects of treatment.

**C11 modulates both total filament mass and number but does not affect length distribution.** Well-characterized electron microscopy methods were utilized to assay the effect of C11 treatment at the level of individual filaments. Individual filament lengths were quantified using the Image J program and total filament length and number were determined for each grid and expressed as percent control. Treatment with 0.001 µM C11 resulted in a significant decrease (p=0.01) in filament number relative to control. In contrast, average filament number significantly increased (p=0.01) to 207.96 percent of control following incubation with 1 µM C11 (Figure 6.A). Similar to filament number, at 0.001 µM C11 average total filament length was significantly reduced (p<0.001) to 23.63 percent of total length obtained from control slices. In addition, significantly higher (p<0.001) total filament mass at the time of tissue collection was achieved with the higher dose (317.1 percent compared to control slices) (Figure 6.B). No significant change was seen in the filament length distribution at either dose (Figure 6.C,D). In both dosing regimes, the distribution was exponential for control and treated samples. This suggests that changes in filament mass and number are not the result of random breakage. This is not insignificant as breakage may produce further nucleation sites.

**C11 treatment does not affect slice viability.** Additional immunoblots were performed to assess the effect of C11 treatment on slice viability, synaptic and cytoskeletal integrity (Figure 6). No changes were seen in levels of cleaved Poly (ADP-ribose) polymerase (PARP) indicating that C11 treatment at either dose does not result in activation of pro-apoptotic caspases (90.9 ± 28.4 for 0.001 µM, 90.04 ± 21.1 for 1 µM). Similarly, in both dosing regimes, no significant change in the level of synaptophysin immunoreactivity was detected (117.3 ± 26.5 for 0.001 µM, 92.2 ± 26.6 for 1 µM). Tubulin levels were likewise unchanged in cultures incubated with 0.001 µM C11 (103.4 ± 25.8). However, when dosed with 1 µM, a significant reduction in tubulin concentration was detected (20.4 ± 22.7). Additional immunoblots from the sarkosyl insoluble fraction of tau revealed the presence of tubulin at significantly higher levels relative to control samples (data not shown). This result suggests that the increased tau polymerization observed following high dose C11 treatment results in tubulin being sequestered into the intracellular tau aggregates.

**Inhibitory doses of C11 do not affect microtubule binding.** Because C11 is capable of binding tau, it is necessary to assess whether this binding interferes with the protein’s ability to interact with tubulin. Slices were treated as described above with either 1 or 0.001 µM C11 versus DMSO vehicle (Figure 7). Again, total tau levels relative to control remained unchanged (91.1 ± 8.6 for 1 µM, 104.4 ± 11.8 for 0.001 µM). When incubated with 0.001 µM, treated slices showed no change in the ratio of microtubule bound (93.5 ± 12.9) and unbound tau (94.1 ± 11.7). Indeed, the majority of tau in the cells was microtubule bound with only faint immunoreactivity in the unbound supernatant fraction. These results indicate that at sub-micromolar concentrations, C11 does not appear to affect normal tau-microtubule interaction. In contrast, addition of 1 µM C11 to the culture media resulted in a significant shift in the pattern of tau binding with treated slices, showing marked microtubule detachment relative to control slices. This is unsurprising considering the sequestration of tubulin with tau aggregates at this dose.

**C11 alters tau polymerization in split GFP tau transfected cells.** Following transfection, cells were incubated overnight prior to addition of C11. GFP fluorescence steadily decreased in both untreated controls and cells dosed with 1 µM C11.
(Figure 9). However both the rate and extent of the decrease was augmented in response to high dose C11. A 50 ± 0.97 percent reduction if GFP fluorescence (from 35993 fluorescence units to 18460) was observed in control cells after three days in culture, reflecting the increase in tau aggregates. Cells treated with 1 µM C11 showed a 62 ± 1.27 percent loss of GFP signal (from 32065 to 12326) reflecting a significantly greater degree of tau aggregation relative to control. Indeed, at each time-point, treated cells showed significantly reduced fluorescence (p<0.001) suggesting accelerated aggregate formation. In order to ascertain whether treatment with low concentrations of C11 reduced tau polymerization, cells were allowed to incubate without treatment for two days in culture to accumulate aggregates. C11 was then added to the media and cells were incubated with the drug for a further two days. Following treatment, fluorescence was measured. As before, fluorescence decreased progressively in control cells with a final value of 78 ± 2.7 percent of control (from 34854 to 27327). Significantly higher fluorescence was obtained in 0.01 µM treated cells relative to control. Indeed, incubation with the drug for three days resulted in no significant loss of GFP signal, indicating that polymerized tau did not accumulate at this dose. These data indicate a shift of the dose response curve in different culture systems. However, though the inhibitory dose differs, in both systems 1 mM C11 led to increased aggregation. In the organotypic slices 0.001 µM was the optimal dose whereas in cells a ten fold higher dose was required to prevent polymerization. Indeed, inhibition is possible at submicromolar concentrations without affecting normal microtubule binding or adverse effects on synaptic integrity. As a control, a similar molecule (C2) determined to be inactive in vitro was utilized to assess non-specific effects of the cyanine skeleton. No changes were seen in the relative amounts of total, soluble and polymerized tau relative to untreated slices. Further, no changes were seen in tubulin, synaptophysin or cleaved PARP with C2 treatment. In addition, effects on polymerization were not dependent on alterations in tau phosphorylation, indicating that a reduction in occupancy at phospho-epitopes is not required to reduce tau filament burden. These results also suggest that increased levels of soluble, hyperphosphorylated tau monomers are not toxic to the slice cultures. However, at present, slices have only been incubated with C11 for one week in culture. It may require longer periods of incubation, or additional assay methods for toxicity to become apparent. Further, these results have been confirmed using a second model system. In these studies, low doses of C11 were capable of significantly reducing the levels of aggregated tau in cells transfected with the longest human tau isoform. In contrast, treatment with 1 µM C11 produced a significant elevation of polymerized tau with a marked decrease in the levels of soluble tubulin. This was accompanied by an increase in tubulin in the sarkosyl insoluble fraction. Studies utilizing N744 suggest that a possible mechanism by which cyanine dyes facilitate tau polymerization is through competitive binding. Dye polymers were capable of displacing tau from the surface of negatively charged polystyrene microspheres and thus raising the concentration of tau in solution. A similar process may be occurring in the slice cultures. Incubation with higher doses of C11 may result in the displacement of tau from the microtubule surface. This would result in an

In vitro studies have shown that small molecule cyanine dyes are capable of selectively binding to abnormally folded tau protein and modulating its polymerization in a biphasic, dose dependent manner [25]. We have shown that it is possible to recapitulate these results in an organotypic slice culture system. Cyanine dye C11 is capable of either significantly reducing, or increasing the levels of sarkosyl insoluble tau. Indeed, inhibition is possible at submicromolar concentrations without affecting normal microtubule binding or adverse effects on synaptic integrity. As a control, a similar molecule (C2) determined to be inactive in vitro was utilized to assess non-specific effects of the cyanine skeleton. No changes were seen in the relative amounts of total, soluble and polymerized tau relative to untreated slices. Further, no changes were seen in tubulin, synaptophysin or cleaved PARP with C2 treatment. In addition, effects on polymerization were not dependent on alterations in tau phosphorylation, indicating that a reduction in occupancy at phospho-epitopes is not required to reduce tau filament burden. These results also suggest that increased levels of soluble, hyperphosphorylated tau monomers are not toxic to the slice cultures. However, at present, slices have only been incubated with C11 for one week in culture. It may require longer periods of incubation, or additional assay methods for toxicity to become apparent. Further, these results have been confirmed using a second model system. In these studies, low doses of C11 were capable of significantly reducing the levels of aggregated tau in cells transfected with the longest human tau isoform.

Discussion

Insoluble tau polymers accumulate in affected cells in a host of neurodegenerative conditions. Identification of compounds capable of reducing the burden of aggregated tau could potentially result in the creation of disease-modifying therapies. One such example, Methylthioninium chloride (Methylene Blue, Rember™), which has been shown to reduce tau fibrillization in vitro [24, 47], is the subject of clinical trials.
increase in the concentration of tau available for incorporation into aggregates. Additionally, previous studies have shown that several microtubule associated proteins such as MAP 1 and 2 can be sequestered into neurofibrillary lesions and the sarkosyl insoluble fraction. It may be that additional MAPs are also being recruited into the sarkosyl insoluble fraction and this loss of support results in the destabilization of the microtubules. This destabilization could then allow tubulin dimers to be likewise sequestered in the sarkosyl insoluble fraction. Loss of tubulin and increased tau filament burden does not, however, appear to result in increased toxicity after one week. No loss of synaptic integrity or activation of pro-apoptotic caspases was observed. On a superficial level, slices treated with 1 µM C11 did not appear less healthy than control, neutral, or low dose treated cultures. As stated above, longer incubation times may be necessary to observe toxic effects. Further studies will be necessary in order to fully evaluate the consequences of altered tau polymerization.

Similar to N744, the dose response relationship of C11 indicates the existence of a therapeutic index. Among compounds that act on amyloid-forming proteins, this is not unheard of. A similar dose response effect was observed with Congo Red in models of Huntington’s disease. In vitro, Congo Red has a monophasic and steep dose response curve [48]. However, in biological models, a more complex pattern emerges. Low concentrations inhibited huntingtin polymerization with higher doses resulting in relief of that inhibition [49]. Similarly, although it retains its biphasic shape, the dose response curve of C11 shifts depending on the model system utilized. Although this may limit the utility of C11, it should be noted that a 100-1000 fold increase in concentration is required in order to promote tau aggregation. Additionally, these results indicate that results obtained in animals or tissue culture with aggregation inhibitors identified in vitro must be interpreted carefully. Indeed, what may appear to be a negative result may in fact occur because the dose response curve has shifted due to changing model systems. This may result in promising compounds being abandoned unnecessarily.

Finally, these findings further demonstrate the potential utility of cyanine dyes. This class of molecules has also been successfully used in cell culture as inhibitors of nitric oxide production [50]. In addition, a cyanine dye, Platonin, has been shown to reduce tissue damage and improve survival in a rat model of heat stroke [51]. Cyanines have also demonstrated utility as contrast agents [52, 53] and one, Cardio Green, has been approved for use in humans. Together with the results described above, these data indicate the potential of this class of compounds for further development as potential therapies.
References

1. Farah, C.A., et al., *Tau interacts with Golgi membranes and mediates their association with microtubules*. Cell Motil Cytoskeleton, 2006. 63(11): p. 710-24.

2. Magnani, E., et al., *Interaction of tau protein with the dynactin complex*. Embo J, 2007. 26(21): p. 4546-54.

3. Braak, H., et al., *Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry*. Acta Neuropathol, 2006. 112(4): p. 389-404.

4. Braak, H. and E. Braak, *Neuropathological staging of Alzheimer-related changes*. Acta Neuropathol, 1991. 82(4): p. 239-59.

5. Giannakopoulos, P., et al., *Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease*. Neurology, 2003. 60(9): p. 1495-500.

6. Gomez-Isla, T., et al., *Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease*. Ann Neurol, 1997. 41(1): p. 17-24.

7. Cras, P., et al., *Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease*. Acta Neuropathol, 1995. 89(4): p. 291-5.

8. Barghorn, S., et al., *Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias*. Biochemistry, 2000. 39(38): p. 11714-21.

9. von Bergen, M., et al., *Tau aggregation is driven by a transition from random coil to beta sheet structure*. Biochim Biophys Acta, 2005. 1739(2-3): p. 158-66.

10. von Bergen, M., et al., *Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure*. J Biol Chem, 2001. 276(51): p. 48165-74.

11. Eckermann, K., et al., *The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy*. J Biol Chem, 2007. 282(43): p. 31755-65.

12. Callahan, L.M. and P.D. Coleman, *Neurons bearing neurofibrillary tangles are responsible for selected synaptic deficits in Alzheimer's disease*. Neurobiol Aging, 1995. 16(3): p. 311-4.

13. Hoglinger, G.U., et al., *The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy*. J Neurochem, 2005. 95(4): p. 930-9.

14. Kraemer, B.C., et al., *Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy*. Proc Natl Acad Sci U S A, 2003. 100(17): p. 9980-5.

15. Callahan, L.M., W.A. Vaules, and P.D. Coleman, *Progressive reduction of synaptophysin message in single neurons in Alzheimer disease*. J Neuropathol Exp Neurol, 2002. 61(5): p. 384-95.

16. Chalmers, K.A. and S. Love, *Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons*. J Neuropathol Exp Neurol, 2007. 66(2): p. 158-67.

17. Bandyopadhyay, B., et al., *Tau aggregation and toxicity in a cell culture model of tauopathy*. J Biol Chem, 2007. 282(22): p. 16454-64.
18. Khlistunova, I., et al., *Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs*. J Biol Chem, 2006. 281(2): p. 1205-14.
19. Khlistunova, I., et al., *Inhibition of tau aggregation in cell models of tauopathy*. Curr Alzheimer Res, 2007. 4(5): p. 544-6.
20. Pickhardt, M., et al., *Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells*. J Biol Chem, 2005. 280(5): p. 3628-35.
21. Crowe, A., et al., *High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation*. Biochem Biophys Res Commun, 2007. 358(1): p. 1-6.
22. Pickhardt, M., et al., *N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy*. Curr Alzheimer Res, 2007. 4(4): p. 397-402.
23. Pickhardt, M., et al., *Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells*. Biochemistry, 2007. 46(35): p. 10016-23.
24. Taniguchi, S., et al., *Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins*. J Biol Chem, 2005. 280(9): p. 7614-23.
25. Chirita, C., M. Necula, and J. Kuret, *Ligand-dependent inhibition and reversal of tau filament formation*. Biochemistry, 2004. 43(10): p. 2879-87.
26. Congdon, E.E., et al., *Potency of a tau fibrillization inhibitor is influenced by its aggregation state*. Arch Biochem Biophys, 2007. 465(1): p. 127-35.
27. Necula, M., C.N. Chirita, and J. Kuret, *Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases*. Biochemistry, 2005. 44(30): p. 10227-37.
28. Chang, E., et al., *Structure-Activity Relationship of Cyanine Tau Aggregation Inhibitors*. J Med Chem, 2009.
29. Chun, W., G.S. Waldo, and G.V. Johnson, *Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage*. J Neurochem, 2007. 103(6): p. 2529-39.
30. Duff, K., et al., *Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes*. Neurobiol Dis, 2000. 7(2): p. 87-98.
31. Tucker, K.L., M. Meyer, and Y.A. Barde, *Neurotrophins are required for nerve growth during development*. Nat Neurosci, 2001. 4(1): p. 29-37.
32. Andorfer, C., et al., *Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms*. J Neurochem, 2003. 86(3): p. 582-90.
33. Duff, K., et al., *Organotypic slice cultures from transgenic mice as disease model systems*. J Mol Neurosci, 2002. 19(3): p. 317-20.
34. Greenberg, S.G. and P. Davies, *A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis*. Proc Natl Acad Sci U S A, 1990. 87(15): p. 5827-31.
35. Petrov, N., et al., *Photophysical Properties of 3,3'-Diethylthiacarbocyanine Iodide in Binary Mixtures*. Journal of Physical Chemistry A, 2003. 107(33): p. 6341-6344.
36. Vogelsberg-Ragaglia, V., et al., Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell, 2000. 11(12): p. 4093-104.
37. Chirita, C.N., et al., Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry, 2005. 44(15): p. 5862-72.
38. Congdon, E.E., et al., Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem, 2008. 283(20): p. 13806-16.
39. Necula, M. and J. Kuret, Electron microscopy as a quantitative method for investigating tau fibrillization. Anal Biochem, 2004. 329(2): p. 238-46.
40. Jeganathan, S., et al., Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-I) conformation. J Biol Chem, 2008. 283(46): p. 32066-76.
41. Liu, F., et al., Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci, 2007. 26(12): p. 3429-36.
42. Sato, S., et al., Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem, 2002. 277(44): p. 42060-5.
43. Rankin, C.A., Q. Sun, and T.C. Gamblin, Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener, 2007. 2: p. 12.
44. Noble, W., et al., Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A, 2005. 102(19): p. 6990-5.
45. Perez, M., et al., Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis, 2003. 5(4): p. 301-8.
46. Bhat, R., et al., Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem, 2003. 278(46): p. 45937-45.
47. Wischik, C.M., et al., Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A, 1996. 93(20): p. 11213-8.
48. Heiser, V., et al., Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci U S A, 2000. 97(12): p. 6739-44.
49. Smith, D.L., et al., Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol Dis, 2001. 8(6): p. 1017-26.
50. Tseng, H.Y., et al., Benzothiazolium compounds: novel classes of inhibitors that suppress the nitric oxide production in RAW264.7 cells stimulated by LPS/IFNgamma. Bioorg Med Chem Lett, 2005. 15(8): p. 2027-32.
51. Tsai, C.C., et al., Platonin, a cyanine photosensitizing dye, is effective for attenuation of heatstroke in rats. Shock, 2006. 26(6): p. 601-7.
52. Licha, K., et al., Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol, 2000. 72(3): p. 392-8.
53. Volkova, K.D., et al., *Cyanine dye-protein interactions: looking for fluorescent probes for amyloid structures*. J Biochem Biophys Methods, 2007. **70**(5): p. 727-33.

**Acknowledgements**

This work was supported by a grant from NIH/NINDS (NS047447) to KD and (AG14452) to Jeff Kuret, the ADDF/ISOA, and the Rosalinde and Arthur Gilbert Foundation/AFAR New Investigator Award in Alzheimer’s Disease.
Figure Legends

Figure 1. Preparation of organotypic slices.
A. Brains were removed from hTau pups between 9 and 11 days postnatal. Olfactory bulb and brainstem are removed and the hemispheres (cortex/hippocampus) were separated. B. Each hemisphere was sectioned into 400 µm slices. C. Slices from each hemisphere were plated in tissue culture inserts on different rows in six well plates. This method allows each animal to act as its own control thus eliminating the problem of variability due to differing pathology between individual animals.

Figure 2. Structure of cyanine dye C11

Figure 3. C11, but not C2 treatment modulates tau polymerization.
Slice cultures were treated as described with 0.001, 0.1, 1 µM C11 (n=6 per group) or 0.001 µM C2 (n=5). A-D. Immunoblotting was carried out on the total (Tot), soluble (S), and sarkosyl insoluble (I) fractions. Blots were incubated with CP27, a monoclonal antibody recognizing all six human tau isoforms, and bands were visualized. Images were quantified using Multigauge v3.0 and expressed as percentage of control signal. E. Following treatment with 0.001 µM C11, total tau levels remained unchanged (107.6 ± 15.7). Soluble tau levels increased to 112 ± 9 percent control (p = 0.01) Sarkosyl insoluble tau was reduced to 55.5 ± 27.7 percent of that of control slices (p = 0.003). F. Slices dosed with 0.1 µM showed no change in levels of total (98.03 ± 6.8) soluble (101.3 ± 7.9) or aggregated (94.1 ± 10.6) tau. G. Incubation with 1 µM C11 resulted in no change in total (94.1 ± 6.53) or soluble (108 ± 22.5) tau levels relative to control. Insoluble tau levels increased (p = 0.001) with treatment (305.43 ± 86.9). H. The inactive cyanine C2 showed no changes in the levels of total, soluble, or insoluble tau relative to control slices.

Figure 4. C11 is internalized and concentrated in slice cultures.
A. Untreated homogenate was incubated in triplicate for 24 hours at 37°C with varying (1.0-0.003 µM) concentrations of C11. Fluorescence signal was then plotted against C11 concentration and a linear curve fit to the data (y = 10442x ± 128.17). B. In 0.001 µM treated (T) and control (C) slices (n=6 mice per group) fluorescence was 183 ± 61.7 and 80.2 ± 33.3 respectively. C. Average fluorescence was measured in homogenates (n=6 per group) of 1 µM C11 treated (T) and control (C) slices. Values obtained were 32504.8 ± 8212.9 and 153.8 ± 38.9 respectively. Utilizing the equation of the standard curve, C11 concentration in 1 µM and 0.001 µM treated samples was estimated as 3.1 µM and 0.0053 µM respectively.

Figure 5. Incubation with C11 does not affect phosphorylation.
A. Aliquots from the heat stable fraction were used to determine the relative levels of phosphorylation at disease and polymerization relevant epitopes. B-F. Immunoblots were processed and quantified as described. No changes were seen in band intensity or mobility relative to control for (B) Thr212 (106.3 ± 7.6 for 1 µM, 111.02 ± 26.4 for 0.001 µM, 112.2 ± 9.6 for C1), (C) Ser262 (93.2 ± 9.6 for 1 µM, 106.1 ± 12.3 for 1 µM, 86.9 ± 8.6 for C1), (D) Ser396 (101.2 ± 13.7 for 1 µM, 116.6 ± 13.5 for 0.001 µM, 93.8 ± 6.7 for C1), (E) AT8 (100.8 ± 5.3 for 1 µM, 102.8 ± 12.6 for 0.001 µM, 106.4 ± 10.62 for C1), or (F) PHF-1 (97.8 ± 13.8 for 1 µM, 100.04 ± 18.03 for 0.001 µM, 106.4 ± 10.6 for C1).

Figure 6. C11 treatment results in changes in filament mass and number.
Filaments in the sarkosyl insoluble fraction were negatively stained with uranyl acetate. Image J was used to measure total filament length obtained for each electron micrograph and the average for each condition was calculated. A. Total filament number as a percentage of control was determined. A significant increase (p=0.01) was observed at 1 µM (207.96 percent) while treatment with 0.001 µM produced a significant decrease (p=0.01) (76.24 percent of control). B. Significantly higher (p<0.001) total filament mass was observed at 1 µM C11 (317.1 percent of control). In contrast 0.001 µM treated samples showed a significant reduction (p<0.001) to 23.63 percent of control values. C,D. The number of filaments falling into each 10 nm length range was determined and expressed as a percentage of total filament number. Distributions were similar for control (black bars) and treated (grey bars) samples.

**Figure 7.** C11 treatment does not negatively affect slice viability
Total protein fractions were assayed for relative levels of cleaved PARP, tubulin and synaptophysin in order to ascertain the health of the cultures. A. Slices incubated with 1 µM C11 showed no difference in cleaved PARP (CP) (92.2 ± 26.5) or synaptophysin (S) (90.04 ± 21.1) signal relative to control however, a marked decrease in tubulin (T) immunoreactivity was observed (44.5 ± 27.5). B. No changes in the relative concentration of any of the proteins was observed with 0.001 µM C11 (90.9 ± 28.4 for cleaved PARP, 117.3 ± 26.5 for synaptophysin, 103.8 ± 28.5 for tubulin).

**Figure 8.** High dose, but not low dose C11 treatment affects microtubule binding
An assay of tau-microtubule binding was performed. Total, microtubule-bound and unbound (free) tau was assessed by immunoblotting. A, C. Following incubation with 1 µM C11 no change in the level of total tau (91.1 ± 8.6) was observed. However, a decrease in microtubule-bound (53.8 ± 12.6) and an increase in free tau (150.9 ± 5.8) were found compared with DMSO-treated controls. B, D. No change in the relative concentration of total (104.4 ± 11.8), microtubule-bound (93.5 ± 12.9), or free tau (94.06 ± 11.7) was observed with 0.001 µM C11.

**Figure 9.** C11 treatment alters tau polymerization in a cellular, tau aggregation assay system.
A. GFP-Tau transfected HEK cells were incubated in culture for 24 hours. Cells were then incubated with either DMSO vehicle (■) or 1 µM C11 (□) for a further two days. Fluorescence in control cells decreased 50 ± 0.97 % during incubation (from 35993.8 fluorescence units to 18011.8). However, drug treatment resulted in a 62 ± 1.27% decrease in fluorescence (from 32696.4 to 12326.1 units), indicating that 1 µM C11 significantly increased tau polymerization. B. Cells were allowed to incubate in culture for two days prior to treatment to accumulate polymerized tau. Following this, cells were treated with either DMSO vehicle (■) or 0.01 µM C11 (□). Fluorescence in vehicle treated cells decreased 22 ± 2.78% from 34854 to 27237. In contrast, treated cells demonstrated no significant loss of signal (35436 to 33835).
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.
Figure 8.
Figure 9.
Inhibition of tau polymerization with a cyanine dye in two distinct model systems
Erin E. Congdon, Yvette H. Figueroa, Lili Wang, Galina Tonuva, Edward Chang, Jeff Kuret, Christopher Conrad and Karen E. Duff

J. Biol. Chem. published online May 28, 2009

Access the most updated version of this article at doi: 10.1074/jbc.M109.016089

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts